Neonatal Research Unit, Health Research Institute La Fe, Valencia, Spain.
University of Valencia, Valencia, Spain.
Hum Reprod. 2018 Jul 1;33(7):1237-1246. doi: 10.1093/humrep/dey109.
Does in vitro fertilization (IVF) affect the course of anxiety and depressive symptoms as well as physiological stress from pregnancy to postpartum period?
IVF mothers have more anxiety symptoms and higher stress biomarker levels but fewer depression symptoms than natural conception mothers at the third trimester of pregnancy, but these differences are negligible during postpartum period.
Cross-sectional studies have found an association between IVF and high stress levels during the prenatal period. There is, however, no follow-up study about the IVF effect on the mental health status from pregnancy to postpartum, adopting simultaneous measurement of self-reported symptoms and stress biomarkers.
STUDY DESIGN, SIZE, DURATION: This is a prospective cohort study. A total of 243 eligible women were recruited during the third trimester of pregnancy (60 women after successful IVF and 183 who conceived naturally). The recruitment was performed during a 12-month period, and the follow-up was carried out until 3 months after delivery.
PARTICIPANTS/MATERIALS, SETTING, METHODS: This study was performed in the Division of Obstetrics in a regional referral center. The State scale of the State-Trait Anxiety Inventory (STAI-S) and the Beck Depression Inventory-Sort Form (BDI/SF) were used as anxiety and depression indicators, respectively; salivary cortisol and α-amylase levels as stress biomarkers. Anxiety, depression and stress biomarkers were measured at the third trimester of pregnancy (T1), at 48 h after birth (T2) and at 3 months after birth (T3). Associations with IVF were assessed using ordinal mixed models for anxiety and depressive symptoms and linear quantile models for stress biomarkers.
Relative to natural conception mothers, IVF mothers had higher STAI-S scores at T1 (P = 0.016, odds ratio (OR) = 2.46), and this difference remained steady from T1 to T2 (P = 0.37, OR = 0.70) and from T2 to T3 (P = 0.36, OR = 0.69). In the case of depressive symptoms, the IVF group obtained lower BDI/SF scores at T1 (P < 0.001, OR = 0.192). This difference was apparently reduced from T1 to T2 (P = 0.072, OR = 2.21) and remained constant from T2 to T3 (P = 0.107, OR = 2.09). It is important to note that whereas the mean BDI/SF score was not clinically significant for any group (it was lower than the cut-off 4), the mean STAI-S score of the IVF group at T1 was so (it was higher than the cut-off 19). As for stress biomarkers, IVF mothers had higher cortisol levels at T1 (P = 0.043, Δlog(cortisol) = 0.88) compared to natural conceptions. From T1 to T2 cortisol levels of both groups increased at the relatively same rate (P = 0.81, Δlog(cortisol) = -0.16). However, the progressions tended to be different from T2 to T3, with IVF mothers exhibiting a sharp decrease in cortisol levels (P = 0.059, Δlog(cortisol) = -0.94), while natural conceptions value remained steady. In the case of α-amylase, there were no statistically significant differences between both groups at T1 (P = 0.7, Δlog(α-amylase) = -0.095). On the contrary, while IVF mothers showed sustained α-amylase levels across the time, the progression was different in the natural conception group, who showed a decrease in α-amylase levels from T1 to T2 (P = 0.049, Δlog(α-amylase) = 0.596) and a non-significant increase from T2 to T3 (P = 0.53, Δlog(α-amylase) = -0.283).
Since this follow-up study has been carried out from the third trimester of pregnancy, the findings cannot be generalized to extremely preterm births.
IVF women may have lower depressive symptoms for being pregnant. However, due to the potential pregnancy complications associated with IVF, they may have higher physiological stress and clinically significant anxiety at the third trimester of pregnancy but not during postpartum. Taking into account that both prenatal high maternal cortisol levels and prenatal clinically significant anxiety increase the risk of disturbance in the fetal neurodevelopment, psychological therapy should be extended during pregnancy in IVF women.
STUDY FUNDING/COMPETING INTEREST(S): MV funded by FIS PI17/0131 grant from the Instituto de Salud Carlos III (ISCIII) and RETICS funded by the PN 2018-2011, and the European Regional Development Fund, reference RD16/0022/0001; AG-B funded by a 'Juan Rodés' Grant (JR17/00003) from the ISCIII. CC-P funded by a 'Miguel Servet I' Grant (CP16/00082) from the ISCIII. Authors declare no competing interests.
体外受精(IVF)是否会影响焦虑和抑郁症状的发展过程以及妊娠到产后期间的生理应激?
与自然受孕母亲相比,在妊娠晚期,IVF 母亲的焦虑症状更明显,应激生物标志物水平更高,但抑郁症状较少,但在产后期间,这些差异可以忽略不计。
横断面研究发现 IVF 与产前期间的高压力水平之间存在关联。但是,尚无关于从妊娠到产后 IVF 对心理健康状况影响的随访研究,同时测量自我报告的症状和应激生物标志物。
研究设计、规模、持续时间:这是一项前瞻性队列研究。在妊娠晚期(成功进行 IVF 的 60 名妇女和 183 名自然受孕的妇女)招募了 243 名符合条件的妇女。招募期为 12 个月,随访时间为产后 3 个月。
参与者/材料、地点、方法:本研究在区域转诊中心的妇产科进行。使用状态特质焦虑量表(STAI-S)和贝克抑郁自评量表-短式(BDI/SF)作为焦虑和抑郁指标,唾液皮质醇和α-淀粉酶水平作为应激生物标志物。在妊娠晚期(T1)、产后 48 小时(T2)和产后 3 个月(T3)测量焦虑、抑郁和应激生物标志物。使用 ordinal mixed models 评估与 IVF 相关的焦虑和抑郁症状,使用线性分位数模型评估应激生物标志物。
与自然受孕母亲相比,IVF 母亲在 T1 时的 STAI-S 评分更高(P = 0.016,优势比(OR)= 2.46),并且这种差异从 T1 到 T2(P = 0.37,OR = 0.70)和从 T2 到 T3(P = 0.36,OR = 0.69)保持稳定。在抑郁症状方面,IVF 组在 T1 时的 BDI/SF 评分较低(P < 0.001,OR = 0.192)。从 T1 到 T2,这种差异明显减少(P = 0.072,OR = 2.21),从 T2 到 T3 保持不变(P = 0.107,OR = 2.09)。需要注意的是,虽然任何一组的 BDI/SF 评分均低于临床显著值(低于 4 分),但 IVF 组在 T1 时的 STAI-S 评分却如此(高于 19 分)。至于应激生物标志物,IVF 母亲在 T1 时的皮质醇水平较高(P = 0.043,Δlog(cortisol) = 0.88)与自然受孕相比。从 T1 到 T2,两组的皮质醇水平以相同的速度增加(P = 0.81,Δlog(cortisol) = -0.16)。然而,从 T2 到 T3 的进展趋势有所不同,IVF 母亲的皮质醇水平急剧下降(P = 0.059,Δlog(cortisol) = -0.94),而自然受孕的皮质醇水平保持稳定。在α-淀粉酶方面,两组在 T1 时没有统计学上的显著差异(P = 0.7,Δlog(α-amylase) = -0.095)。相反,虽然 IVF 母亲的α-淀粉酶水平持续稳定,但在自然受孕组中,α-淀粉酶水平从 T1 到 T2 呈下降趋势(P = 0.049,Δlog(α-amylase) = 0.596),从 T2 到 T3 呈非显著增加(P = 0.53,Δlog(α-amylase) = -0.283)。
由于这项随访研究是从妊娠晚期开始进行的,因此研究结果不能推广到极早产儿。
IVF 女性可能在怀孕期间出现较低的抑郁症状。然而,由于与 IVF 相关的潜在妊娠并发症,她们在妊娠晚期可能会出现较高的生理应激和临床显著的焦虑,但在产后期间不会出现。考虑到产前高母体皮质醇水平和产前临床显著的焦虑均会增加胎儿神经发育障碍的风险,应在 IVF 女性怀孕期间延长心理治疗。
研究资金/利益冲突:MV 由 FIS PI17/0131 资助,来自 ISCIII 和 RETICS,由 PN 2018-2011 和欧洲区域发展基金资助,参考 RD16/0022/0001;AG-B 由 ISCIII 的“Juan Rodés”资助(JR17/00003)。CC-P 由 ISCIII 的“Miguel Servet I”资助(CP16/00082)。作者没有利益冲突。